# Eastman Kodak Co: financial statements, quarterly KODK · NYSE · CIK 31235 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kodk.md) · [Financials](/companies/kodk/financials.md) · [Filings](/companies/kodk/filings.md) · [Insiders](/companies/kodk/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kodk/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [269](/filings/0001437749-24-034553.md) | [275 d](/filings/0001193125-26-104214.md) | [249](/filings/0000950170-25-067006.md) | [267](/filings/0000950170-25-106568.md) | [261](/filings/0001193125-25-269608.md) | [266 d](/filings/0001193125-26-104214.md) | [247](/filings/0001193125-26-212026.md) | [263](/filings/0001193125-26-332850.md) | [269](/filings/0001193125-25-269608.md) | [290 d](/filings/0001193125-26-104214.md) | [265](/filings/0001193125-26-212026.md) | [311](/filings/0001193125-26-332850.md) | | Cost of revenue | $m | [219](/filings/0001437749-24-034553.md) | [228 d](/filings/0001193125-26-104214.md) | [200](/filings/0000950170-25-067006.md) | [209](/filings/0000950170-25-106568.md) | [216](/filings/0001193125-25-269608.md) | [215 d](/filings/0001193125-26-104214.md) | [201](/filings/0001193125-26-212026.md) | [212](/filings/0001193125-26-332850.md) | [201](/filings/0001193125-25-269608.md) | [223 d](/filings/0001193125-26-104214.md) | [208](/filings/0001193125-26-212026.md) | [229](/filings/0001193125-26-332850.md) | | Gross profit | $m | [50.0](/filings/0001437749-24-034553.md) | [47.0 d](/filings/0001193125-26-104214.md) | [49.0](/filings/0000950170-25-067006.md) | [58.0](/filings/0000950170-25-106568.md) | [45.0](/filings/0001193125-25-269608.md) | [51.0 d](/filings/0001193125-26-104214.md) | [46.0](/filings/0001193125-26-212026.md) | [51.0](/filings/0001193125-26-332850.md) | [68.0](/filings/0001193125-25-269608.md) | [67.0 d](/filings/0001193125-26-104214.md) | [57.0](/filings/0001193125-26-212026.md) | [82.0](/filings/0001193125-26-332850.md) | | Research and development | $m | [7.0](/filings/0001437749-24-034553.md) | [9.0 d](/filings/0001193125-26-104214.md) | [9.0](/filings/0000950170-25-067006.md) | [8.0](/filings/0000950170-25-106568.md) | [8.0](/filings/0001193125-25-269608.md) | [8.0 d](/filings/0001193125-26-104214.md) | [9.0](/filings/0001193125-26-212026.md) | [9.0](/filings/0001193125-26-332850.md) | [7.0](/filings/0001193125-25-269608.md) | [8.0 d](/filings/0001193125-26-104214.md) | [8.0](/filings/0001193125-26-212026.md) | [9.0](/filings/0001193125-26-332850.md) | | Selling, general and administrative | $m | [40.0](/filings/0001437749-24-034553.md) | [45.0 d](/filings/0001193125-26-104214.md) | [45.0](/filings/0000950170-25-067006.md) | [47.0](/filings/0000950170-25-106568.md) | [44.0](/filings/0001193125-25-269608.md) | [43.0 d](/filings/0001193125-26-104214.md) | [45.0](/filings/0001193125-26-212026.md) | [41.0](/filings/0001193125-26-332850.md) | [41.0](/filings/0001193125-25-269608.md) | [47.0 d](/filings/0001193125-26-104214.md) | [48.0](/filings/0001193125-26-212026.md) | [53.0](/filings/0001193125-26-332850.md) | | Operating income | $m | [2.0](/filings/0001437749-24-034553.md) | [(13.0) d](/filings/0001193125-26-104214.md) | [7.0](/filings/0000950170-25-067006.md) | [2.0](/filings/0000950170-25-106568.md) | [(8.0)](/filings/0001193125-25-269608.md) | [(8.0) d](/filings/0001193125-26-104214.md) | [(13.0)](/filings/0001193125-26-212026.md) | [(5.0)](/filings/0001193125-26-332850.md) | [19.0](/filings/0001193125-25-269608.md) | [(1.0) d](/filings/0001193125-26-104214.md) | [(1.0)](/filings/0001193125-26-212026.md) | [15.0](/filings/0001193125-26-332850.md) | | Interest expense | $m | [14.0](/filings/0001437749-24-034553.md) | [16.0 d](/filings/0001193125-26-104214.md) | [15.0](/filings/0000950170-25-067006.md) | [15.0](/filings/0000950170-25-106568.md) | [14.0](/filings/0001193125-25-269608.md) | [15.0 d](/filings/0001193125-26-104214.md) | [14.0](/filings/0001193125-26-212026.md) | [15.0](/filings/0001193125-26-332850.md) | [18.0](/filings/0001193125-25-269608.md) | [15.0 d](/filings/0001193125-26-104214.md) | [6.0](/filings/0001193125-26-212026.md) | [6.0](/filings/0001193125-26-332850.md) | | Income tax | $m | [(2.0)](/filings/0001437749-24-034553.md) | [4.0 d](/filings/0001193125-26-104214.md) | [3.0](/filings/0000950170-25-067006.md) | [1.0](/filings/0000950170-25-106568.md) | [3.0](/filings/0001193125-25-269608.md) | [1.0 d](/filings/0001193125-26-104214.md) | [2.0](/filings/0001193125-26-212026.md) | [2.0](/filings/0001193125-26-332850.md) | [3.0](/filings/0001193125-25-269608.md) | [9.0 d](/filings/0001193125-26-104214.md) | [3.0](/filings/0001193125-26-212026.md) | [4.0](/filings/0001193125-26-332850.md) | | Net income | $m | [2.0](/filings/0001437749-24-034553.md) | [5.0 d](/filings/0001193125-26-104214.md) | [32.0](/filings/0001193125-25-269608.md) | [26.0](/filings/0001193125-25-269608.md) | [18.0](/filings/0001193125-25-269608.md) | [26.0 d](/filings/0001193125-26-104214.md) | [(7.0)](/filings/0001193125-26-332850.md) | [(26.0)](/filings/0001193125-26-332850.md) | [13.0](/filings/0001193125-25-269608.md) | [(108) d](/filings/0001193125-26-104214.md) | [(16.0)](/filings/0001193125-26-332850.md) | [17.0](/filings/0001193125-26-332850.md) | | Diluted EPS | $ per share | [0.00](/filings/0001437749-24-034553.md) | not reported | [0.30](/filings/0000950170-25-067006.md) | [0.23](/filings/0000950170-25-106568.md) | [0.15](/filings/0001193125-25-269608.md) | not reported | [(0.12)](/filings/0001193125-26-212026.md) | [(0.36)](/filings/0001193125-26-332850.md) | [(0.08)](/filings/0001193125-25-269608.md) | not reported | [(0.21)](/filings/0001193125-26-212026.md) | [0.13](/filings/0001193125-26-332850.md) | | Basic EPS | $ per share | [0.00](/filings/0001437749-24-034553.md) | not reported | [0.31](/filings/0000950170-25-067006.md) | [0.25](/filings/0000950170-25-106568.md) | [0.16](/filings/0001193125-25-269608.md) | not reported | [(0.12)](/filings/0001193125-26-212026.md) | [(0.36)](/filings/0001193125-26-332850.md) | [(0.08)](/filings/0001193125-25-269608.md) | not reported | [(0.21)](/filings/0001193125-26-212026.md) | [0.13](/filings/0001193125-26-332850.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [246](/filings/0001437749-23-030954.md) | [255](/filings/0000950170-25-040256.md) | [262](/filings/0001437749-24-015681.md) | [251](/filings/0001437749-24-025552.md) | [214](/filings/0001437749-24-034553.md) | [201](/filings/0001193125-26-104214.md) | [158](/filings/0000950170-25-067006.md) | [155](/filings/0000950170-25-106568.md) | [168](/filings/0001193125-25-269608.md) | [337](/filings/0001193125-26-332850.md) | [299](/filings/0001193125-26-212026.md) | [290](/filings/0001193125-26-332850.md) | | Current assets | $m | [712](/filings/0001437749-23-030954.md) | [712](/filings/0000950170-25-040256.md) | [677](/filings/0001437749-24-015681.md) | [660](/filings/0001437749-24-025552.md) | [642](/filings/0001437749-24-034553.md) | [595](/filings/0001193125-26-104214.md) | [577](/filings/0000950170-25-067006.md) | [574](/filings/0000950170-25-106568.md) | [592](/filings/0001193125-25-269608.md) | [841](/filings/0001193125-26-332850.md) | [793](/filings/0001193125-26-212026.md) | [766](/filings/0001193125-26-332850.md) | | Total assets | $m | [2,357](/filings/0001437749-23-030954.md) | [2,355](/filings/0000950170-25-040256.md) | [2,347](/filings/0001437749-24-015681.md) | [2,359](/filings/0001437749-24-025552.md) | [2,388](/filings/0001437749-24-034553.md) | [2,001](/filings/0001193125-26-104214.md) | [1,937](/filings/0000950170-25-067006.md) | [1,933](/filings/0000950170-25-106568.md) | [2,075](/filings/0001193125-25-269608.md) | [1,617](/filings/0001193125-26-332850.md) | [1,557](/filings/0001193125-26-212026.md) | [1,527](/filings/0001193125-26-332850.md) | | Current liabilities | $m | [271](/filings/0001437749-23-030954.md) | [283](/filings/0000950170-25-040256.md) | [274](/filings/0001437749-24-015681.md) | [278](/filings/0001437749-24-025552.md) | [266](/filings/0001437749-24-034553.md) | [261](/filings/0001193125-26-104214.md) | [261](/filings/0000950170-25-067006.md) | [729](/filings/0000950170-25-106568.md) | [749](/filings/0001193125-25-269608.md) | [268](/filings/0001193125-26-332850.md) | [314](/filings/0001193125-26-212026.md) | [263](/filings/0001193125-26-332850.md) | | Total liabilities | $m | [1,190](/filings/0001437749-23-030954.md) | [1,214](/filings/0000950170-25-040256.md) | [1,184](/filings/0001437749-24-015681.md) | [1,184](/filings/0001437749-24-025552.md) | [1,190](/filings/0001437749-24-034553.md) | [1,142](/filings/0001193125-26-104214.md) | [1,154](/filings/0000950170-25-067006.md) | [1,183](/filings/0000950170-25-106568.md) | [1,214](/filings/0001193125-25-269608.md) | [904](/filings/0001193125-26-332850.md) | [885](/filings/0001193125-26-212026.md) | [830](/filings/0001193125-26-332850.md) | | Long-term debt | $m | [451](/filings/0001437749-23-030954.md) | [457](/filings/0000950170-25-040256.md) | [447](/filings/0001437749-24-015681.md) | [453](/filings/0001437749-24-025552.md) | [460](/filings/0001437749-24-034553.md) | [466](/filings/0001193125-26-104214.md) | [473](/filings/0000950170-25-067006.md) | [11.0](/filings/0000950170-25-106568.md) | [10.0](/filings/0001193125-25-269608.md) | [208](/filings/0001193125-26-332850.md) | [108](/filings/0001193125-26-212026.md) | [108](/filings/0001193125-26-332850.md) | | Current portion of debt | $m | [1.0](/filings/0001437749-23-030954.md) | [1.0](/filings/0000950170-25-040256.md) | [1.0](/filings/0001437749-24-015681.md) | [1.0](/filings/0001437749-24-025552.md) | [1.0](/filings/0001437749-24-034553.md) | [1.0](/filings/0001193125-26-104214.md) | [2.0](/filings/0000950170-25-067006.md) | [479](/filings/0000950170-25-106568.md) | [497](/filings/0001193125-25-269608.md) | [1.0](/filings/0001193125-26-332850.md) | [52.0](/filings/0001193125-26-212026.md) | [2.0](/filings/0001193125-26-332850.md) | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [959](/filings/0001437749-24-034553.md) | [931](/filings/0001193125-26-104214.md) | [951](/filings/0001193125-25-269608.md) | [961](/filings/0001193125-25-269608.md) | [982](/filings/0001193125-25-269608.md) | [641](/filings/0001193125-26-332850.md) | [563](/filings/0001193125-26-332850.md) | [528](/filings/0001193125-26-332850.md) | [762](/filings/0001193125-25-269608.md) | [614](/filings/0001193125-26-332850.md) | [600](/filings/0001193125-26-332850.md) | [623](/filings/0001193125-26-332850.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [0.0 d](/filings/0001437749-24-034553.md) | [17.0 d](/filings/0001193125-26-104214.md) | [17.0](/filings/0000950170-25-067006.md) | [(7.0) d](/filings/0000950170-25-106568.md) | [(21.0) d](/filings/0001193125-25-269608.md) | [4.0 d](/filings/0001193125-26-104214.md) | [(38.0)](/filings/0001193125-26-212026.md) | [8.0 d](/filings/0001193125-26-332850.md) | [21.0 d](/filings/0001193125-25-269608.md) | [489 d](/filings/0001193125-26-104214.md) | [(30.0)](/filings/0001193125-26-212026.md) | [5.0 d](/filings/0001193125-26-332850.md) | | Capital expenditure | $m | [4.0 d](/filings/0001437749-24-034553.md) | [17.0 d](/filings/0001193125-26-104214.md) | [10.0](/filings/0000950170-25-067006.md) | [9.0 d](/filings/0000950170-25-106568.md) | [20.0 d](/filings/0001193125-25-269608.md) | [17.0 d](/filings/0001193125-26-104214.md) | [12.0](/filings/0001193125-26-212026.md) | [12.0 d](/filings/0001193125-26-332850.md) | [4.0 d](/filings/0001193125-25-269608.md) | [6.0 d](/filings/0001193125-26-104214.md) | [6.0](/filings/0001193125-26-212026.md) | [5.0 d](/filings/0001193125-26-332850.md) | | Dividends paid | $m | [1.0 d](/filings/0001437749-24-034553.md) | [1.0 d](/filings/0001193125-26-104214.md) | [1.0](/filings/0000950170-25-067006.md) | [1.0 d](/filings/0000950170-25-106568.md) | [1.0 d](/filings/0001193125-25-269608.md) | [1.0 d](/filings/0001193125-26-104214.md) | [1.0](/filings/0001193125-26-212026.md) | [1.0 d](/filings/0001193125-26-332850.md) | [0.0 d](/filings/0001193125-25-269608.md) | [0.0 d](/filings/0001193125-26-104214.md) | [3.0](/filings/0001193125-26-212026.md) | [1.0 d](/filings/0001193125-26-332850.md) | | Share repurchases | $m | [0.0 d](/filings/0001437749-24-034553.md) | [0.0 d](/filings/0001193125-26-104214.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-269608.md) | [0.0 d](/filings/0001193125-26-104214.md) | [1.0](/filings/0001193125-26-212026.md) | [1.0 d](/filings/0001193125-26-332850.md) | [0.0 d](/filings/0001193125-25-269608.md) | [5.0 d](/filings/0001193125-26-104214.md) | [0.0](/filings/0001193125-26-212026.md) | [2.0 d](/filings/0001193125-26-332850.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [79.0](/filings/0001437749-23-030954.md) | [92.2](/filings/0001437749-24-015681.md) | [93.0](/filings/0001437749-24-025552.md) | [79.5](/filings/0001437749-24-034553.md) | [91.3](/filings/0000950170-25-067006.md) | [92.4](/filings/0000950170-25-106568.md) | [92.7](/filings/0001193125-25-269608.md) | [80.6](/filings/0001193125-26-212026.md) | [80.9](/filings/0001193125-26-332850.md) | [89.8](/filings/0001193125-25-269608.md) | [97.5](/filings/0001193125-26-212026.md) | [103](/filings/0001193125-26-332850.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 97,900,000 at 2026-07-29, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332850.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.